NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...

Protagonist Therapeutics, Inc. surged 30% after Johnson & Johnson expressed acquisition interest, driven by the need to offset Stelara's declining sales. PTGX's lead assets, Icotrokinra and Rusfertide ...

Every great story has memorable characters, but not all of them play the same role. While the protagonist usually takes center stage, other key characters help shape the narrative in equally important ...

Online, November 18, 2024 (Newswire.com) - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ...

NEWARK, Calif., June 30, 2025 (Newswire.com) - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG ...

Shueisha’s Shonen Jump is responsible for creating some of the most iconic characters and series in the anime and manga industry, helping popularize the shonen genre around the world. While shonen ...

Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral ...